Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
October 2011, Vol 2, No 6
October 2011, Vol 2, No 6
Recent Ruling on Genetic Patents Leaves Many Questions
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
October 2011, Vol 2, No 6
On July 29, 2011, a 3-judge panel from the US Court of Appeals for the Federal Circuit invalidated some patents held by Myriad Genetics and the University of Utah Research Foundation for methods of analyzing individuals’ gene sequences for the presence of BRCA1 and BRCA2 mutations, but upheld other related patents in a reversal of a lower court ruling.
Read Article
Concurrent Chemotherapy and Radiation Therapy Extends Survival in NSCLC
In the Literature
October 2011, Vol 2, No 6
The concurrent use of chemotherapy and thoracic radiotherapy (TRT) confers a greater survival benefit in patients with stage III non–small-cell lung cancer (NSCLC) than a sequential use of these therapies, based on results from a phase 3 clinical study (Curran WJ, et al. J Natl Cancer Inst. 2011;103: 1452-1460).
Read Article
Survivorship Programs an Emerging Need, But Are They Cost-Effective?
By
Caroline Helwick
Policies & Guidelines
,
Survivorship Care
October 2011, Vol 2, No 6
The population of cancer survivors is rapidly growing. More than 12 million Americans are alive after a cancer diagnosis: most are living at least 5 years and 16% are alive 20 years after diagnosis.
Read Article
Order of Initial Breast Cancer Treatment Does Not Affect Outcomes
By
Audrey Andrews
Breast Cancer Symposium
October 2011, Vol 2, No 6
Whether women receive chemotherapy or surgery first as their initial treatment for breast cancer does not affect long-term localregional recurrence, according to a large case series from the University of Texas M.D. Anderson Cancer Center, Houston, that was presented at the 2011 Breast Cancer Symposium.
Read Article
Occult Metastases Do Not Warrant Axillary Dissection in Breast Cancer
By
Audrey Andrews
Breast Cancer Symposium
October 2011, Vol 2, No 6
San Francisco, CA—The debate over the clinical significance of occult micrometastases in the lymph nodes of patients with breast cancer continues.
Read Article
Targeted Radiation Therapy Gaining Momentum
By
Caroline Helwick
ASCO Breast Cancer Symposium
October 2011, Vol 2, No 6
San Francisco, CA—Accelerated partial breast irradiation using brachytherapy (APBIb) for breast cancer has been rapidly adopted in the United States, although its use varies by region, race, and ethnicity. Jona A. Hattangadi, MD, Harvard Radiation Oncology Program, Boston, reported the findings at the 2011 ASCO Breast Cancer Symposium, which was sponsored by 6 breast, oncology, and surgical societies.
Read Article
Breast Cancer Treatment Still Under Par for Patients Covered by Medicaid
By
Audrey Andrews
Breast Cancer Symposium
October 2011, Vol 2, No 6
San Francisco, CA—Several studies presented at the 2011 Breast Cancer Symposium shed light on the quality of breast cancer care received by women who are uninsured or receiving Medicaid.
Read Article
Novel HDAC Inhibitor Improves Outcomes in Patients with Estrogen-Sensitive Breast Cancer
By
Audrey Andrews
October 2011, Vol 2, No 6
San Francisco, CA—A novel histone deacetylase (HDAC) inhibitor, when added to the aromatase inhibitor exemestane (Aromasin), appears to restore sensitivity to the endocrine agent by significantly delaying recurrences and creating an increased survival trend.
Read Article
Noise-Canceling Information
By
Ron Ribitzky, MD
Oncology
October 2011, Vol 2, No 6
New discoveries in diagnosis, treatment, and prevention of cancer abound, but what is just “noise”? What is in oncology that is interesting, intriguing, inspiring, yet still just “noise,” because the path to action “here and now” is missing, or not obvious?
Read Article
Nilotinib Sustains 24-Month Superiority to Imatinib in CML
In the Literature
October 2011, Vol 2, No 6
The BCR-ABL inhibitor nilotinib (Tasigna) was developed as a selective treatment for patients with chronic myeloid leukemia (CML) who are not responding appropriately to imatinib (Gleevec) therapy.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma